PedAM
Pediatric Disease Annotations & Medicines
| Disease | thalassemia |
| Symptom | |iron overload |
| Sentences | 80 |
| PubMedID- 24646011 | Moreover, chronic conditions associated with ineffective erythropoiesis, such as non-transfusion-dependent thalassaemia (ntdt), may lead to iron overload through increased gut absorption of iron starting in childhood. |
| PubMedID- 19756955 | Hepcidin mutation in a beta-thalassemia major patient with persistent severe iron overload despite chelation therapy. |
| PubMedID- 22052662 | Electrocardiographic consequences of cardiac iron overload in thalassemia major. |
| PubMedID- 25850001 | Furthermore, a pilot trial investigating the effect of amlodipine (a ccb) on iron overload in patients with thalassemia major reported that it can serve as a complementary treatment to standard chelation regimens and may improve the efficacy of iron removal in the heart without the burden of significant side effects . |
| PubMedID- 23516830 | In this study production levels of interleukins (il)-12 and il-13 were measured by commercial elisa in culture supernatants of mitogen-stimulated peripheral blood mononuclear cells-from 30 non-splenectomized beta-thalassaemia cases with iron overload and 20 age- and sex-matched healthy individuals. |
| PubMedID- 22089614 | In southeast asia, both thalassaemias with iron overload and patients with iron deficiency co-exist in the same population. |
| PubMedID- 24044606 | Cardiac complications represent the leading cause of mortality in thalassemia major with uncontrolled iron overload. |
| PubMedID- 24847266 | iron overload in patients with beta-thalassemia major lead to alterations in the arterial structures and in the thickness of the carotid arteries (cheung et al., 2002; tantawy et al., 2009). |
| PubMedID- 25878400 | recently reviewed the iron chelating activity of african walnut and wheat grass extracts as to their potential for natural iron removal agents for iron overload associated with thalassemia, which is currently typically treated clinically with desferal. |
| PubMedID- 23687960 | iron overload in beta-thalassaemia major patients is secondary to multiple blood transfusions and increased iron absorption. |
| PubMedID- 23966105 | Authors' conclusions: in the absence of data from randomised controlled trials, there is no evidence to suggest the need for a change in current treatment recommendations; namely that deferiprone is indicated for treating iron overload in people with thalassaemia major when desferrioxamine is contraindicated or inadequate. |
| PubMedID- 25801075 | Methods and materials: in this quasi-experimental study, serum ferritin levels were evaluated in 32 beta-thalassemia major patients with severe iron overload before and after receiving combined deferasirox (30-40 mg kg(-1) day(-1) ) and deferoxamine (40-50 mg kg(-1) day(-1) ) 2 days a week. |
| PubMedID- 24460526 | Myocardial iron overload in thalassaemia major. |
| PubMedID- 23834310 | Combination therapy of deferasirox and deferoxamine shows significant improvements in markers of iron overload in a patient with beta-thalassemia major and severe iron burden. |
| PubMedID- 23228075 | Recently it has been used to detect myocardial dysfunction related to iron overload in patients with beta-thalassemia . |
| PubMedID- 26205801 | Objectives: 'the aim of this work was to compare the efficacy of different iron chelating agents' in the treatment of ' iron overload in children with beta thalassemia major'. |
| PubMedID- 23241074 | Conclusion: we conclude that the use of dfx instead of dfo represents a cost-effective use of resources for treatment of iron overload in patients with beta-thalassemia from iran's society perspective. |
| PubMedID- 20662901 | Conclusion: transfusional iron overload in patients with thalassaemia could be reduced to normal body iron range levels using effective deferiprone/deferoxamine combinations. |
| PubMedID- 23019522 | Moreover, a review article that addresses the mechanism of tissue damage arising from iron overload in patients with β-thalassemia major is presented. |
| PubMedID- 23426199 | iron overload in beta-thalassemia intermedia: an emerging concern. |
| PubMedID- 22933160 | Effect of iron overload on endocrinopathies in patients with beta-thalassaemia major and intermedia. |
| PubMedID- 23460118 | However, in the case of patient with primary myelofibrosis the magnetic anisotropy energy barrier differed from that in normal case and, probably, the iron core size was supposed to be slightly larger than that in both normal spleen tissue and normal human liver ferritin in contrast to well-known data for iron overload in patients with thalassemia accompanied by the iron-core size increase. |
| PubMedID- 22066516 | Relation between nt-probnp levels, iron overload, and early stage of myocardial dysfunction in beta-thalassemia major patients. |
| PubMedID- 23600689 | Assessment and management of iron overload in beta-thalassaemia major patients during the 21st century: a real-life experience from the italian webthal project. |
| PubMedID- 21757620 | Reproductive capacity in iron overloaded women with thalassemia major. |
| PubMedID- 26114738 | Efficacy of deferasirox (exjade(r)) in modulation of iron overload in patients with beta-thalassemia intermedia. |
| PubMedID- 22023452 | Although the evidence for the benefits of iron chelation therapy to treat iron overload in patients with thalassaemia is unequivocal and well founded, its use in patients with mds remains controversial because of a lack of definitive evidence documenting its benefits (10). |
| PubMedID- 25822525 | Tnf-α and il-10 were found to be elevated in iron overloaded patients with thalassemia major . |
| PubMedID- 20027547 | Dual-echo tfe mri for the assessment of myocardial iron overload in beta-thalassemia major patients. |
| PubMedID- 24934354 | The hepatic iron overload in beta-thalassemia patients is associated with haemosiderin storage both in kupffer cells and in the cytoplasm of hepatocytes. |
Page: 1 2